Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dawson, J. K.
Right arrow Articles by Lynch, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dawson, J. K.
Right arrow Articles by Lynch, M. P.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 803-804
© 2003 British Society for Rheumatology

Letters to the Editor

Reply

J. K. Dawson and M. P. Lynch

Department of Rheumatology, St Helens Hospital, Marshalls Cross Road, St Helens, Merseyside, UK

The first 10% of the full text of this article appears below.

We thank Dr Provenzano for his interest in our recent article, and are encouraged by his supportive findings. We are concerned about the interchangeable use of the terms ‘methotrexate pulmonary toxicity’, ‘methotrexate pneumonitis' and ‘chronic pulmonary fibrosis caused by methotrexate’. We wish to clarify that the described complications of low-dose methotrexate are acute hypersensitivity pneumonitis, drug-induced asthma, pulmonary fibrosis, accelerated pulmonary nodulosis and infection with Pneumocystis . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?